CRB Health Tech

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

Bio&Tech Smart Capital is the alliance of researchers and entrepreneurs with Venture Capital management professionals to transfer scientific knowledge to society, with the aim of transforming spin off projects and startups that emerge from universities into solid and profitable companies. innovation laboratories and institutions. Investment criteria Bio&Tech Smart Capital focuses its activity focus on: Digital technologies applied to life sciences (focus on automation and data science). Biotechnology. Diagnostics and medical devices. Sustainability. Selected for the combination of: social impact, potential profitability and the experience and knowledge of the sector of the team. Diversification : no sector will represent more than 50% of the invested capital.

Our goal is to optimize value creation across all stages of our investment journey; from clinical trials and FDA approvals, through market validation and product adoption, to successful entry into capital markets and strategic deals. Driving HealthTech from business plan to business success Our unique strategic ecosystem and team’s active engagement help portfolio companies realize their full potential and achieve large-scale success. By providing unparalleled access to invaluable resources in the form of: Clinical infrastructures KOLs Big data Domain experts Financial backing We help our companies gain an in-depth understanding of clinical workflows and procedures, to ensure product-market fit under challenging health economics, deliver better care for patients and create value to all stake holders. We invest in the right fit We invest in promising mid-to-late stage companies developing innovative platform technologies that will become the gold standard in a broad range of disciplines. The main areas of focus include: Medical devices Diagnostics Digital health Healthcare IT AI and ML We look for highly fundable companies with strong management, broad IP protection and a proven track record of execution, that are poised to benefit from the strategic synergies offered by the ALIVE ecosystem.

VentureBlick is a super incubator for medtech. We provide a fully customisable one-stop solution to develop, test, and market healthcare innovations. Leveraging our global advisor network, the deep industry roots of our founding team, and extensive partnership, VentureBlick streamlines the startup journey, from ideation and testing to venture building and market success. ​ Our global VB Advisory Network has more than 1,200 medical and industry advisors, from more than 50 countries covering over 30 specialty areas. They play important roles in different capacities and different stages of startup development, to help accelerate innovations. ​ VentureBlick was founded in 2022 by senior healthcare executive, Chris Lee, with the vision of helping healthcare startups thrive. ​ We are headquartered in Singapore with presences in Australia, China, Germany, India, Korea, and USA.

Established in 2023, KP Rx is a 100% founder-owned investment firm specialising in private and early-stage public healthcare investments in Australia and New Zealand. Founded by Hashan De Silva and backed by Karst Peak Capital, the firm targets high-potential biotech, medical devices, diagnostics, and health tech companies at a pivotal inflection point of value creation. Our Focus Creating a portfolio of Australia’s most promising healthcare companies. Our focus is on companies at or after Series A, specifically biotech companies at Phase 2 or medical device companies at or after regulatory clearance. Small-molecule Drugs Biological Products Cell & Gene Therapies Medical Devices Diagnostic Technologies AI for Healthcare Healthcare Software / SaaS Data and Analytics

Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. Why Gilmartin Capital? The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas. In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.